gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MNKDHealthcarePharmaceuticals

Mannkind Corporation (MNKD)

$3.75−4.61%
Close Nov 5, 2026 · split-adjusted
Nov 4, 2026$3.93▼ 28.28% in range
Nov 4, 2025Low $2.28 · High $6.21Nov 4, 2026
What changed · written from our data
As of Nov 5, 2026

Mannkind closed at $3.75 on Nov 5, down 4.61%, 39.6% below its 52-week closing high. Volume of 2.3M shares was 0.66× its 20-day average (below normal).

Split-adjusted performance: +8.7% over one month, +5.6% over six months, -31.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $109.37M, up 42.9% from a year earlier, with a net margin of -17.4%.

Short interest was 25.5M shares at the Oct 15 settlement, down 2.6% from the prior report (8.2% of float, 5.1 days to cover).

Market cap$1.21B321.5M shares
Revenue · quarter$109.4M+42.9% YoY
Diluted EPS$-0.06—
P/E · TTM—P/S 3.1×
Net margin-17.4%Gross 73.0%
Dividend yieldNone
52-week range2.28 – 6.21−39.6% from high
Volume2.3M0.66× 20-day avg
Volatility · 60d58.1%Annualised
Short % of float8.2%5.1 days to cover
Net cash-$373.9MCash $111.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.1%1M +8.7%3M −8.8%6M +5.6%YTD −33.9%1Y −31.6%3Y −12.6%5Y −21.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 418 companies (100 = best)

6-month momentum76
Revenue growth76
Net margin59
Value (low P/E)—
Size72

Industry medians: 6-month return −27.4%, revenue growth +5.9%, net margin −37.5%, P/E 15.1×.

Short interest

Details →
Shares short25.5M−2.6% vs prior
Days to cover5.1Settled Oct 15
% of float8.2%
Short vol. 10d55.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MNKDMannkind$3.75−4.61%+5.6%+42.9%−17.4%—$1.21B
AMPHAmphastar Pharmaceuticals$27.86−0.59%+15.9%+5.4%16.5%15.1$1.18BCompare
NKTRNektar Therapeutics$36.01−6.42%−56.8%−9.3%−401.0%—$1.23BCompare
AVLNAvalyn Pharma$26.55−3.35%————$1.18BCompare
OMEROmeros$17.17−5.56%+17.3%—46.4%10.0$1.24BCompare
LBRXLB Pharmaceuticals$38.74−5.18%+21.1%———$1.25BCompare
OPKOpko Health$1.69−4.47%+51.0%+4.3%−5.1%—$1.26BCompare
VSTMVerastem$9.48−3.81%+67.4%+1775.4%−86.5%—$1.15BCompare
URGNUroGen Pharma$26.21−8.80%−1.4%+199.2%−19.8%—$1.29BCompare

News about Mannkind

All news →
MannKind to Participate in the Chardan Healthcare ConferenceGlobeNewswire Inc. · Oct 14, 2026▲ PositiveMannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)GlobeNewswire Inc. · Oct 10, 2026▲ PositiveData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsGlobeNewswire Inc. · Jun 5, 2026▲ PositiveMannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalGlobeNewswire Inc. · May 29, 2026▲ PositiveMannKind to Present at Jefferies Global Healthcare ConferenceGlobeNewswire Inc. · May 27, 2026▲ Positive

Quick answers

What does Mannkind do?
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
What is MNKD's market cap?
$1.21B, based on the Nov 5 close of $3.75.
Does Mannkind pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MNKD is sold short?
25.5M shares, 8.2% of float, as of Oct 15, 2026.
What sector is MNKD in?
Healthcare, in the Pharmaceuticals industry.

About Mannkind

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

HQ: Danbury, CT592 employeesListed Jul 28, 2004mannkindcorp.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology